The molecular mechanisms determining the transmissibility and prevalence of drug-resistant tuberculosis in a population were investigated through whole-genome sequencing of 1,000 prospectively obtained patient isolates from Russia. Two-thirds belonged to the Beijing lineage, which was dominated by two homogeneous clades. Multidrug-resistant (MDR) genotypes were found in 48% of isolates overall and in 87% of the major clades. The most common rpoB mutation was associated with fitness-compensatory mutations in rpoA or rpoC, and a new intragenic compensatory substitution was identified. The proportion of MDR cases with extensively drug-resistant (XDR) tuberculosis was 16% overall, with 65% of MDR isolates harboring eis mutations, selected by kanamycin therapy, which may drive the expansion of strains with enhanced virulence. The combination of drug resistance and compensatory mutations displayed by the major clades confers clinical resistance without compromising fitness and transmissibility, showing that, in addition to weaknesses in the tuberculosis control program, biological factors drive the persistence and spread of MDR and XDR tuberculosis in Russia and beyond.
Tuberculosis is the second leading cause of death from an infectious disease after HIV. In 2011, there were an estimated 8.7 million new cases and 1.4 million deaths from the disease 1 . The increasing prevalence of drug resistance is a major public health concern that threatens the progress made in controlling drug-sensitive tuberculosis 2 . Globally, 4% of new cases and 20% of previously treated cases are estimated to have MDR tuberculosis, defined as resistance to at least rifampicin and isoniazid, with the highest proportions in Eastern Europe and Central Asia 1 . MDR cases require prolonged, costly treatment with toxic second-line drugs, and rates of treatment failure and mortality are high [2] [3] [4] . XDR strains, which are MDR strains with additional resistance to any fluoroquinolone and at least one second-line injectable agent (kanamycin, amikacin or capreomycin), have now been found in every region of the world 1 . Globally, the proportion of MDR tuberculosis cases with XDR tuberculosis has reached 9%. In the UK, 26 XDR cases were reported between 1995 and 2011; 45% (9/20) of the patients with known country of birth originated from Eastern Europe 5 . Recent years have seen an ominous accumulation of reports of 'totally' drug-resistant strains, which are not susceptible to any tested drugs 6 .
Prevalence of drug-resistant tuberculosis is dependent on the rate of acquisition of resistance-conferring mutations (acquired resistance) and the rate of transmission of drug-resistant strains (primary resistance). In Mycobacterium tuberculosis, drug resistance arises through chromosomal mutation, typically resulting in a fitness cost seen as a reduced growth rate in vitro 7 . Fitness cost generally inversely correlates with the frequency of a mutation in clinical isolates 8 . Compensatory mutations mitigating the deleterious effects of resistance-conferring mutations are also important in determining the transmissibility of specific genotypes 9 . Studies using molecular epidemiological clustering rates to assess the transmission cost of resistance-associated genotypes report varying results 10, 11 , suggesting that fitness costs may be affected by epistasis: that is, the phenotypic effect of a mutation depends on the presence or absence of other mutations in the same genome 12 .
Whole-genome sequencing offers the power to track the evolutionary mechanisms that promote the development and transmission of drug resistance within pathogen populations with unparalleled resolution. Evidence for adaptive selection in response to antibiotic therapy can be found by identifying homoplasies (mutations arising independently multiple times within a phylogeny) or loci that are subject to frequent mutation [13] [14] [15] . By identifying all changes that occur in a genome, it is possible to uncover co-occurring polymorphisms that contribute to resistance phenotypes or signify epistatic effects 12 .
The high incidence of MDR and XDR tuberculosis in Samara 3,16 , a region with over 3 million citizens in Russia, afforded an opportunity to study the emergence and spread of antibiotic resistance within a population. In this prospective study, the largest of its kind A r t i c l e s yet reported, we used whole-genome sequencing to investigate the molecular mechanisms underlying resistance, fitness compensation and positive epistasis that together determine the transmissibility and prevalence of drug-resistant strains. Comparative analysis with XDR isolates from the UK addressed the origin of highly drug-resistant tuberculosis in this low-prevalence country.
RESULTS

Population structure
During a 2-year period (2008-2010), 2,348 M. tuberculosis isolates were prospectively collected from individual patients living in Samara, Russia. The genomes of 1,000 isolates were sequenced. Comparison of patient epidemiological data indicated that this sample was representative of the entire population and covered the distribution of patients with tuberculosis across the whole region ( Fig. 1 and Supplementary Table 1 ). For comparison, we selected 28 sequences from a study of over 2,000 London-based patients with tuberculosis, originating from 90 different countries, as representatives of the global population 17, 18 . We included five phenotypically XDR strains isolated from UK patients in 2011, as well as an isolate from Estonia representing the clone that dominates the M. tuberculosis population of this country 19 .
Mapping reads for each isolate against the reference sequence H37Rv identified a total of 32,445 SNPs in nonrepetitive regions of the genome, including 238 SNPs associated with drug resistance. These variable sites were used to reconstruct a maximum-likelihood phylogeny ( Fig. 2 and Supplementary Data Set 1). Tree topology was consistent with the global phylogenetic structure of M. tuberculosis sensu stricto comprising four main lineages 20, 21 . Of the 1,000 Samaran isolates, 642 belonged to the Beijing lineage, 355 belonged to the Euro-American lineage, 2 belonged to the Central Asian (CAS) lineage and a single isolate belonged to the East African-Indian (EAI) lineage, reflecting the proportions seen in the whole Samaran patient population.
In comparison to the disparate Beijing isolates from the UK, the majority of Samaran Beijing sequences formed a monophyletic group that we term the 'East European' sublineage 18 ( Supplementary Fig. 1 ), consistent with a single relatively recent expansion of this lineage in the region. Bayesian population genetic clustering 22 defined the two largest clades nested within the Beijing lineage-clade A and clade Bcomprising 264 and 119 isolates, respectively ( Supplementary  Fig. 2 ). Outside of these clades, the majority of the remaining Beijing isolates were members of smaller clusters; 60% (387/642) of all Beijing isolates differed from their last common ancestor by 5 or fewer SNPs (Supplementary Fig. 3 ). The western part of Samara is geographically isolated by the River Volga. Comparison of the isolate population in the west to that in the rest of the region showed a significant reduction in the proportion of clade A isolates (18% versus 28%, P = 0.04; Supplementary Fig. 4 and Supplementary Table 2) .
The Euro-American lineage showed significantly higher nucleotide diversity (π = 0.0042, s.d. = 0.00018, 95% confidence interval (CI) = 0.0038-0.0045) than the Beijing lineage (π = 0.0022, s.d. = 0.00039, 95% CI = 0.0015-0.0030). Fewer Euro-American isolates were members of closely related clusters; 39% (137/355) differed from their last common ancestor by 5 or fewer SNPs (P < 0.001). Although global diversity within the Euro-American lineage has not yet been well characterized, Homolka et al. 23 identified eight SNP-based sublineages that were broadly concordant with molecular fingerprint-based classifications. We identified four of these sublineages in Samara (Haarlem, LAM, Ural and S-type), whereas 36% of isolates could not be classified by this scheme (Fig. 2) .
Short genetic distances between isolates have been used to infer the likelihood of direct transmission 24 . In our data set, four pairs of patients with sequenced isolates shared households. Within three A r t i c l e s of these households, the patient isolates were almost identical, with zero, two and three SNPs separating each pair, consistent with intrahousehold transmission or infection from a common source 24 . Patients in the fourth household were infected with unrelated isolates (183 SNPs different). In addition to the household pair, 30 further pairs of isolates, 3 clusters of 3 isolates and 1 cluster of 5 isolates had no SNP differences within the cluster. Patients with identical isolates were resident in the same region of Samara in only 20 of these 35 clusters. By mapping patient addresses, we found that patients with identical strains lived up to 136 km apart (Supplementary Fig. 5 ).
XDR tuberculosis isolates from four UK patients who originated from the Baltic States were members of the East European sublineage, with two belonging to clade B and one belonging to clade A, suggesting that infections may have been acquired during stays in their country of origin or within sympatric communities in the UK (Fig. 2) . In support of this conjecture, the fifth XDR isolate, from a Chinese patient, was not a member of the East European sublineage. The Estonian isolate was also a member of clade B. Correlation of variable-number tandem repeat (VNTR) fingerprint data indicated that this strain is the same one that predominates across northwestern Russia 18, 19, 25 . The East European isolates were remarkably closely related, with isolates from different countries separated by as few as 13 SNPs (Supplementary Table 3 ).
Prevalence of MDR genotypes
A maximum-likelihood phylogeny of the 1,000 Russian isolates was reconstructed and annotated with drug resistance genotypes ( Fig. 3 and Supplementary Tables 4-6 ). The most commonly mutated drug resistance locus, in codon 315 of katG, which confers high-level resistance to isoniazid 26 , was substituted in 74% (478/642) of Beijing isolates and in 30% (106/355) of Euro-American isolates (P < 0.001; Fig. 4 and Supplementary Table 7) . A new nonsense SNP in codon 668 also mediated resistance, consistent with the requirement of KatG for activation of the pro-drug. All (478) of the Beijing katG mutants encoded a p.Ser315Thr substitution, whereas 11% (12/106) of Euro-American isolates encoded 1 of 3 alternative substitutions in codon 315 (P < 0.001).
A total of 70 isolates had mutations in the promoter of the fabG1-inhA operon that confer low-level cross-resistance to isoniazid and its structural analogs, ethionamide and prothionamide 27 . As determined using the phylogenetic reconstruction, the inhA mutation arose in a katG mutant in 44 of the isolates. It is improbable that isoniazid therapy would select for mutations conferring low-level resistance in the presence of a SNP conferring high-level resistance, indicating that the majority of these promoter SNPs were acquired in response to therapy with ethionamide or prothionamide.
Mutations in the 81-bp rifampicin resistance-determining region (RRDR) of rpoB are accurate predictors of rifampicin resistance in M. tuberculosis 28 . Within this region, we identified 20 nonsynonymous SNPs and 2 small deletions, which affected 70% (430/642) of Beijing and 19% (67/355) of Euro-American isolates (P < 0.001). The most common rifampicin resistance genotype, encoding a p.Ser450Leu substitution, was found in 90% (390/435) of Beijing isolates with RRDR mutations and in 67% (45/67) of Euro-American isolates (P < 0.001). Figure 3 Phylogenetic distribution of resistanceconferring and compensatory genotypes. The phylogeny of 1,000 Russian isolates is depicted on the left; lineages are colored as in Figure 2 . The first 16 columns depict drug resistance loci. "P" followed by a subscript gene name indicates mutations affecting the promoter region of the gene. For the 16S rRNA gene, rrs str refers to the 530 stem loop and 915 regions involved in streptomycin resistance 49 , and rrs inj refers to downstream regions associated with resistance to second-line injectable agents 36 . Colored bands represent different polymorphisms and include previously identified and new mutations described in this study. The last three columns show nonsynonymous SNPs in the RNA polymerase genes rpoABC, excluding those in the RRDR. Genotypes shown are provided in full in supplementary table 4. npg A r t i c l e s emerging significantly more frequently in this genetic background (16/435 versus 4/565, P = 0.001). Mutations affecting the most commonly substituted residue, Thr187, were acquired independently at least seven times, providing strong evidence that rpoA is subject On the basis of these genotypes, 66% (422/642) of Beijing and 17% (61/355) of Euro-American isolates have a predicted MDR phenotype (P < 0.001). The proportion of isolates that were MDR in clade A and clade B combined was significantly higher than for the rest of the Beijing lineage (332/383 versus 90/259, P < 0.001).
Compensatory mutations in MDR isolates
We investigated the occurrence of compensatory mutations in rpoA and rpoC 18 in isolates carrying rifampicin resistance mutations. We identified 14 different nonsynonymous SNPs in rpoA, 11 of which were found in isolates containing the rpoB mutation encoding p.Ser450Leu (equivalent to the p.Ser531Leu substitution in Escherichia coli), RpoA   G31S  G31A  K177M  T181A  V183G  E184D   T187P  T187A   D190G  L304R S307L   1  100  200  300   RpoC   G332S  G332R  G332C   N416T  N416S   R572H  N698H  N698S  N698K   A734V   D747A Q761R   R770H  N826K  I832V  S838C   L847R   Y849C D943G G945V P1040T  P1040S  P1040R   I1046M   V1252L  P678R   1  100  200  300  400  500  600  700  800  900  1,000  1,100  1,200  1,300   S428A   V431M   G433S  G433C  P434Q  P434R  K445R   L449V  F452C   V483A  V483G   W484G  D485N  D485Y  I491V  I491T   L516P   V517L   G519D A521D  H525Q  L527V   L42F P45S   E82G   RpoB   T399A   I488V  I491V   V496M  V496L   F503S   D571A  H723Y L731P   E761D  P479T  H835P  H835R   R827C   1  100  200  300  400  500  600  700  800  900  1,000   RRDR   L430P   H445Q   M434V   L430R   Q432P   D435Y   G456S   D435V  D435G   H445N  H445C  H445D  H445L   H445R   S450P  S450L  S450W L452P  H445Y   S431G   S428R 1,100 npg to positive selective pressure. Clustering of SNP sites within three small regions suggests that the encoded residues are important for interaction with the rifampicin-binding pocket (Fig. 5) . Eighteen of the 58 nonsynonymous SNPs identified in rpoC were homoplasic. The nonsynonymous SNPs in rpoC were significantly more likely to arise in isolates harboring an rpoB mutation encoding p.Ser450Leu than in those with wild-type RRDR or other resistance-conferring mutations (76/435 versus 11/565, P < 0.001; Supplementary Table 8 ).
In total, 36 of the 59 amino acid substitutions in RpoA or RpoC found to be associated with the p.Ser450Leu alteration in RpoB had not previously been reported 18, 29 .
Overall, 47% (170/390) of isolates harboring the mutation encoding p.Ser450Leu had a putative compensatory mutation in rpoA or rpoC. However, such compensatory mutations were remarkably infrequent in clade A (Fig. 3 and Supplementary Fig. 6 ); 89% (150/169) of nonclade A Beijing isolates harboring p.Ser450Leu had a nonsynonymous SNP in rpoA or rpoC compared to 9% (20/221) of clade A isolates (P < 0.001). This difference in frequency was unexpected given the obvious epidemiological success of this clade. Thus, we predicted that the large distal cluster of clade A isolates carrying an rpoB mutation encoding p.Ser450Leu harbored alternative compensatory mutations that restored fitness. By inspection of the phylogeny, we deduced the branch on which this putative mutation likely occurred; one of the four SNPs on this branch resulted in a p.Glu761Asp substitution in RpoB (Supplementary Fig. 6 ). Intragenic compensatory mutations in rpoB harboring resistance-conferring mutations have been observed in experimentally evolved E. coli 30 , Pseudomonas aeruginosa 31 and Salmonella enterica 32 . We surmise that the p.Glu761Asp substitution provides an analogous fitness benefit in M. tuberculosis strains carrying the rpoB mutation encoding p.Ser450Leu.
In addition to the p.Glu761Asp substitution and excluding RRDR polymorphisms, a further 26 nonsynonymous SNPs were identified in rpoB. Sixteen of these co-occurred with a mutation encoding p.Ser450Leu (Fig. 5) and were significantly more likely to be found in isolates without alternative compensatory mutations (24/37 versus 2/396, P < 0.001). Multiple substitution events in codons 496 and 835 provide confirmation that regions of rpoB other than the RRDR are under selective pressure. Including all putative compensatory SNPs, 97% (421/435) of isolates carrying an rpoB mutation encoding p.Ser450Leu harbored additional rpoABC mutations, which did not appear in any isolates with wild-type RRDR and may mitigate the deleterious effect of this resistance-conferring mutation.
Sherman et al. 33 proposed that loss of catalase-peroxidase function in isoniazid-resistant katG mutants was compensated by upregulation of alkyl hydroperoxidase, ahpC. We identified four polymorphic sites within the ahpC regulatory region, including two homoplasies. Of the nine isolates harboring ahpC SNPs, four carried a katG mutation encoding p.Ser315Thr, four had a rare katG mutation (encoding p.Ser315Gly or p.Trp668*) and one had wildtype katG. The ahpC SNPs were significantly more likely to arise in isolates with unusual katG mutations (2/12 versus 3/572, P = 0.004), supporting the theory that the p.Ser315Thr alteration has low or no fitness cost 34 .
Prevalence of XDR genotypes
We ascertained that 17% (71/422) of Beijing MDR and 7% (4/61) of Euro-American MDR isolates had genotypes predicting an XDR phenotype (P = 0.046).
Mutations in the eis promoter that confer kanamycin resistance 35 were found in 66% (317/483) of all MDR isolates. Eight different sites were polymorphic, including five homoplasies. eis mutations were significantly more common in isolates belonging to clade A or clade B compared to the rest of the Beijing lineage (275/332 versus 21/90, P < 0.001). Mutations in the drug target rrs, which confer resistance to amikacin and capreomycin, as well as to kanamycin 36 , were found in only 40 isolates, 4 of which had a preexisting SNP in the eis promoter.
Fluoroquinolones target the DNA gyrases GyrA and GyrB, and resistance is conferred by mutations affecting the quinolone resistance-determining regions (QRDRs) that interact with the drugs 37 . Eighty-six isolates harbored mutations affecting the QRDR of GyrA, and 11 Beijing isolates had SNPs affecting the GyrB QRDR. Substitutions in gyrAB arose relatively more often in isolates with rrs mutations than in those with eis promoter mutations (15/40 versus 62/317, P = 0.009; Supplementary Fig. 7) .
In addition to isolates with fluoroquinolone resistance genotypes, we noted a significant number of isolates with ambiguous base calls within the sequences encoding QRDRs (Supplementary Table 9 ). This phenomenon was almost never observed at other drug resistance loci. For 18 isolates with ambiguous gyrA genotypes, ambiguity was often apparent at more than one of the codons (codons 90, 91 and 94) that most commonly confer resistance (Supplementary Fig. 8 ). In inspecting raw sequencing reads mapping to this region, we did not find multiple substitutions that were present on a single read, indicating that multiple fluoroquinolone-resistant clones coexisted in a single patient. Fluoroquinolone treatment of non-tuberculosis infections could drive the acquisition of fluoroquinolone resistance in patients chronically infected with tuberculosis 38 . If this were the case, we would expect to see resistance in non-MDR isolates; however, we found no resistant or heterogeneous QRDR genotypes in non-MDR isolates, indicating that fluoroquinolone exposure occurred as part of tuberculosis therapy.
Adaptive selection at other drug resistance loci
Repeated independent acquisition of SNPs, identified by phylogenetic homoplasy, provides strong evidence of selection 13 (Supplementary Table 10 ). Farhat et al. 14 recently identified 22 new genomic regions that were targets of positive selection in drug-resistant strains (excluding repetitive regions), including 4 that harbored homoplasies in our data set. Using a complementary approach, Zhang et al. 15 identified 98 new regions that were enriched for SNPs in drug-resistant versus drug-sensitive strains, including 11 in which we identified homoplasies.
embB harbored homoplasic mutations in codons 306, 406 and 497 that are commonly associated with ethambutol resistance, although discordance with susceptibility testing is reported 39 . We identified homoplasic mutations in five additional embB codons ( Table 1) . Surprisingly, the most frequent homoplasic embB substitution was p.Asp354Ala, which affected a large cluster of clade A isolates as well as two unrelated isolates. This unusual alteration was associated with phenotypic ethambutol resistance in 50% (83/166) of the isolates tested. Multiple acquisitions of SNPs in the region upstream of embAB provide evidence that operon upregulation also confers resistance 40 . Promoter and coding SNPs frequently co-occurred, and isolates with two mutations were more often phenotypically resistant (27/28 versus 199/375, P < 0.001; Supplementary Table 5), offering an explanation for the poor concordance between embB codon 306 mutations and phenotypic resistance 39 .
The pyrazinamide resistance gene pncA 41 was the most variable gene in the genome ( Table 2 and Supplementary Fig. 9 ). In addition, its promoter harbored five different mutations. gidB was the second most polymorphic gene, indicating that it is a target of selective npg A r t i c l e s pressure and supporting its proposed role in streptomycin resistance 42 . Discounting the common sublineage-defining SNPs 43 , gidB mutations were relatively more common in Euro-American than in Beijing isolates (47/355 versus 16/642, P < 0.001) and were less likely to be concomitant with rpsL or rrs mutations (1/47 versus 13/16, P < 0.001). This skewed distribution suggests that gidB mutations have a lineage-specific effect. ethA, which catalyzes activation of the pro-drug ethionamide 44 , was also among the most highly variable genes in the population. A homoplasic SNP 7 bp upstream of ethA was independently acquired at least twice, both times in clade A. Positive selection of this SNP suggests that it functions clinically in resistance, although only 33% (56/172) of the promoter mutants tested were phenotypically resistant. In total, 84% (409/483) of all MDR isolates carried mutations in ethA or its upstream region.
Transmissibility of drug resistance
Previous studies relied upon fingerprint clustering to estimate the transmission dynamics of drug resistance genotypes 10, 11 . Employing a similar principle but applying the improved resolution of whole-genome sequencing, we investigated transmissibility by using the phylogeny to estimate the number of isolates that independently acquired a SNP versus the number of isolates that inherited that SNP from an inferred common ancestor (indicating primary resistance).
SNPs conferring resistance to rifampicin, isoniazid, streptomycin and ethambutol were significantly more likely to be found in phylogenetic clusters than not (P < 0.05; Fig. 6 and Supplementary Table 11) .
By inferring the order of SNP acquisition events from the phylogenetic tree, we determined that, for 97% (481/495) of isolates with RRDR SNPs, a katG mutation affecting Ser315 occurred before or on the same branch as the RRDR SNP. Hence, phylogenetic clustering of rpoB SNPs is essentially a surrogate for the clustering of MDR genotypes.
The most frequently acquired resistance genotype was for pyrazinamide; the modal number of isolates harboring each pncA coding or promoter polymorphism was 1 (65 of 106 clusters), and only 1 mutation was shared by a phylogenetic cluster of more than 7 isolates. The common pncA nonsynonymous SNP, encoding the conservative substitution p.Ile6Leu, was found in 157 clade A isolates. This SNP was not associated with phenotypic pyrazinamide resistance in vitro (Supplementary Table 5) ; however, no secondary pncA mutations were identified in these isolates.
SNPs in gyrA were significantly less likely to be found in clusters (P = 0.006; Supplementary Table 11); the largest cluster contained 5 isolates, and 59% (52/88) of resistant isolates did not cluster. In contrast, eis promoter SNPs were typically found in large clusters, the most notable of which was a cluster of 207 clade A isolates. npg DISCUSSION In the largest bacterial whole-genome sequencing project reported so far, we provide a region-wide snapshot of the M. tuberculosis population in Samara, Russia. Circulating strains belonged mainly to two lineages: Beijing and Euro-American. In concordance with other Russia-based studies, the Beijing lineage was dominant and accounted for two-thirds of isolates 16, 25 . Relative to isolates from the Beijing lineage, EuroAmerican isolates were phylogenetically diverse, and tree topology supports the division of this lineage into multiple sublineages 23 . Samaran Beijing isolates were essentially monophyletic with respect to isolates representing the global population, forming a group we term the East European sublineage, which was dominated by two clades of extremely limited diversity. Short genetic distance between tuberculosis isolates has been used to infer transmission links 24 . In this population, we found large geographic distances within even identical clusters, suggesting that short SNP distances did not always reflect transmission events or that the importance of casual contact may be underestimated. Genotypes conferring drug resistance were extremely common; 48% of isolates had an MDR genotype, and 16% of these were XDR. In comparison to a small microbiologically based study conducted in Samara in 2001 (ref. 45) , the proportion of MDR isolates resistant to amikacin has remained relatively stable (7.2% versus 8.5%), whereas the frequency of fluoroquinolone resistance has risen substantially from 4.3% to 23.8%. However, fluoroquinolone resistance was significantly more likely to be acquired than other resistance genotypes, indicating that gyrAB mutants may have impaired transmission fitness, impeding the spread of XDR clones. Current rates of resistance support the continued use of fluoroquinolones together with amikacin or capreomycin, rather than kanamycin, for MDR therapy. Whereas a fluoroquinolone in combination with prothionamide was highly effective in the treatment of MDR strains in Lithuania, which has a comparable MDR tuberculosis problem and a similar historical treatment strategy 4 , the frequency of ethA mutations in Russian isolates means that thioamides may be ineffective in this population.
Drug resistance has previously been associated with the Beijing lineage 16 . Here we provide evidence that Beijing isolates are more likely to harbor the isoniazid resistance genotype, conferred by a katG mutation encoding p.Ser315Thr, that has a negligible fitness cost 34 , and the rifampicin resistance genotype, conferred by an rpoB mutation encoding p.Ser450Leu, that we find strongly associated with putative compensatory mutations within the RNA polymerase genes. Other studies have shown that rpoC mutations restored fitness in competitive growth assays 29 and were significantly more common in isolates belonging to a fingerprint cluster than in non-clustered isolates 9 . These observations explain, at least in part, the predominance of Beijing MDR isolates. The widespread use of kanamycin in MDR tuberculosis therapy may further exacerbate the spread of MDR strains by selecting strains with eis mutations that both confer resistance 35 and increase bacterial multiplication in host macrophages 46 by disrupting the protective immune response 47 . Notably, eis mutations were significantly associated with the dominant Beijing clades.
The epidemiological success of clade A strains was particularly striking, and the 'comb-like' structure of the tree, apparent in the distal portion of the clade, suggests a highly infectious clone. The incomplete dispersion of clade A to western Samara supports its recent and rapid spread. From this success, we deduced the presence of unidentified fitness-enhancing mutations, which led to the discovery of new compensatory mutations in rpoB associated with rifampicin resistance. In addition, we surmised that a new SNP upstream of ethA likely confers low-level clinical resistance to ethionamide, not detected in vitro, through promoter disruption or enhanced binding of the EthR repressor 48 . Typically, the most common resistance-conferring SNPs are associated with the least fitness cost 8 , implying that successful clones would carry these SNPs. Thus, the discovery of this new ethA promoter SNP and the rare embB nonsynonymous SNP encoding p.Asp354Ala in clade A was unexpected.
The majority of clade A isolates encoded a conservative p.Ile6Leu substitution in the pyrazinamide resistance gene pncA, which does not confer resistance in vitro and is the only nonsynonymous SNP in pncA found in a large cluster. The deduced frequency of acquired pyrazinamide resistance in the sequenced population, together with the small cluster size associated with primary resistance, suggests that mutants with non-functional PncA have impaired transmission efficiency. Given the prevalence of pyrazinamide resistance in the population, it is difficult to reconcile the epidemiological success of clade A with a pyrazinamide-sensitive phenotype. We speculate that the p.Ile6Leu substitution results in intermediate PncA activity that manifests as pyrazinamide sensitivity in vitro but as clinical resistance in vivo and allows retention of sufficient nicotinamidase activity for efficient transmission.
We propose that the unusual combination of resistance-conferring and compensatory mutations acquired by clade A comprise a 'perfect storm' , providing clinical drug resistance without compromising fitness and transmissibility.
Preventing tuberculosis transmission relies on accurate and rapid diagnosis. Molecular methods that reduce the time taken to detect drug-resistant tuberculosis strains expedite the institution of effective therapy and efficient infection control measures, thus minimizing the infectious period. Whole-genome sequencing offers the potential for rapid, unambiguous determination of all existing clinically relevant drug resistance mutations, and decreasing costs have neutralized a major argument over the value of targeted sequencing relative to whole-genome sequencing. We have reported the existence of multiple mutations in some resistance loci, as well as lineage-and clade-specific association of certain mutations that are suggestive of undiscovered epistatic interactions. These observations indicate that drug resistance may be more multifactorial than previously appreciated, which may in some cases explain discordance between phenotypes and genotypes. As more resistance-conferring loci are identified and the phenotypic effects of multiple mutations and strain background are elucidated, the public health value of routine wholegenome sequencing for the diagnosis of drug resistance will increase, although it may vary depending on prevalence and likely exposure to resistant strains.
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ONLINE METhODS
Study population and whole-genome sequencing. From October 2008 to 2010, 2,348 patients with pulmonary disease and culture-proven tuberculosis were recruited from all 18 civilian tuberculosis dispensaries located across Samara. M. tuberculosis isolates were prospectively archived at the Samara Tuberculosis Service. Anonymized epidemiological data were stored on a password-protected Access database. Informed consent was obtained from all subjects. The study was approved by the Samara Medical Ethics Committee, the Queen Mary Research Ethics Committee and the University of Cambridge Research Ethics Committee.
Isolates were cultured on Middlebrook medium for 4-6 weeks at 37 °C. Sweeps of colonies were harvested and lysed by vortexing with glass beads, and genomic DNA was purified using a DNeasy Blood and Tissue kit (Qiagen). Paired-end multiplex libraries with a mean insert size of 200 bp were prepared as previously described 50 . Sequencing was performed at the Wellcome Trust Sanger Institute on the Illumina Genome Analyzer GAII or HiSeq 2000 platform, generating reads of 54 bp, 75 bp or 100 bp.
Sequence analysis. Sequence reads were aligned to the corrected H37Rv reference genome 18, 51 with SMALT (see URLs), and GATK indel realignment was applied 52 . Pindel 53 was used to predict the positions of indels and structural variants; these variants were visually checked in the mapping files. Candidate SNPs were identified using SAMtools 54 . At each mapped position, alleles were considered to be valid if they were supported by greater than 70% of mapped reads, including at least five in each direction and a minimum mapping quality of 45. SNPs located within repetitive regions were excluded from analysis 18 .
Mixed base calls in nonrepetitive regions of the genome were considered valid if they had mapping quality of ≥45, both calls were supported by at least five reads on each strand, and P values for strand bias, base quality bias, map quality bias and tail distance bias were ≥0.001.
To assess data consistency, nine isolates that were sequenced with 54-bp paired-end reads were recultured, and 100-bp paired-end sequence was generated. For each of these technical replicates, there were no inconsistencies in the bases called at variant sites that passed quality filters in both sequences.
Phylogenetic and population genetic analyses.
A maximum-likelihood phylogeny was reconstructed with RAxML 55 using a general time-reversible model with gamma correction for among-site rate variation. Calculation of 100 bootstrap replicates provided support for nodes on the tree. The phylogenetic tree was visualized with FigTree (see URLs). Ancestral sequences were reconstructed onto each node of the phylogeny using PAML 56 . From these ancestral sequences, SNPs were reconstructed onto branches of the tree.
To statistically define population structure, we used BAPS (Bayesian Analysis of Population Structure) software 57, 58 , in particular its hierBAPS module 22 , which delineates population structure using nested clustering. Three nested levels of molecular variation were fitted to the data using 10 independent runs of the stochastic optimization algorithm with the a priori upper bound of the number of clusters varying over the interval of 50-300 across the runs.
To estimate nucleotide diversity π (ref. 59 ) for the Euro-American and Beijing clades, the functions available in the PGEToolbox 60 were used in parallel on a cluster computing environment. The very large number of sequences in each clade would require excessive amounts of computing resources when analyzing all the sequences in a single process, and, hence, to allow for more economical calculations, 50 random subsets of 100 strains were sampled from each clade, and inference was performed using 100 bootstraps for each of them, as described by Cai et al. 60 , and averaging the results. Confidence intervals for π estimates were computed using the normal distribution approximation with s.d. derived by the bootstrap procedure.
Molecular fingerprinting and microbiological testing. Isolates were characterized by spoligotyping according to standard methods 61 .
Susceptibility to the first-line drugs rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide was determined using the absolute concentration method on Lowenstein-Jensen slopes 62 or by using the automated Mycobacterial Growth Indicator Tube (MGIT) 960 system (Becton Dickinson) 63 . For MDR isolates, susceptibility to the second-line drugs amikacin, capreomycin, ofloxacin, moxifloxacin and prothionamide was also determined using the MGIT system 61 .
A quality assurance procedure was implemented to ensure that isolate metadata corresponded to the appropriate sequence. Data for isolates belonging to the SNP-defined Beijing lineage that did not exhibit the characteristic Beijing spoligotype and, conversely, for isolates in other SNP-defined lineages that shared the Beijing spoligotype were excluded from further analysis (n = 45). The specificity of the katG mutation encoding p.Ser315Thr for the prediction of isoniazid resistance is >99% (ref. 64) ; thus, microbiological data for isolates with this genotype but a sensitive phenotype were also excluded (n = 58).
Statistical methods. Simple descriptive statistics were used to compare patient data for the sample population and the remaining population and to characterize the prevalence of mutations and the geographic distribution of sublineages; 95% confidence intervals (CIs) were established. In addition, the sampled population was evaluated by attributive risk analysis. The significance of differences between studied groups of variables was calculated using two-sample tests of proportions: Pearson χ 2 or Fisher's exact test when any expected group size was less than five. Statistical tests were two-sided at α = 0.05. Analysis was performed using STATA (version 12.1, StataCorp).
